2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Women’s Health, Workforce, Adverse Events, Biological Processes, Apoptosis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3743 Validation of a prognostic score in blast phase CML: A cure CML consortium analysis

Akriti G Jain, MD, FACP, Zhuoer Xie, MD,MS2, Umar Iqbal, MD, MBBS3, Colin Vale4, Anthony Michael Hunter, MD5, Wei Wei, MS6, Kinaya Smith, MD7, Shivani Handa, MD8, Allyson Waller, PharmD, BCOP9, Alice Scott Mims, MD10, Benjamin Joseph McCormick, MD, MS11, Ling Zhang, MD12, Asmita Shukla, MD13, Jay Yang, MD14, Amanda Dailey-Hansen, DNP15, Srinivas Tantravahi, MD16, Suravi Raychaudhuri, MD17, Vivian Oehler, MD18, Jerald Radich, MD19, B. Douglas Smith, MD20, Charles Foucar, MD21, Quinto Gesiotto, MD22, Onyee Chan, MD23, Javier Pinilla-Ibarz, MD PhD24, Talha Badar, MD25, Sudipto Mukherjee, MD, PhD, MPH26, Ehab Atallah, MD27, Kendra L. Sweet, MD, MS28
1 Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, United States, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
2 H. Lee Moffitt Cancer and Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer and Research Institute, Tampa, Florida, United States
4 Winship Cancer Institute of Emory University,, Emory, Georgia, United States
5 Winship Cancer Institute of Emory University,, Emory, Georgia, United States
6 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
9 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
10 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
11 Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Jacksonville, Florida, United States
12 H. Lee Moffitt Cancer and Research Institute, Tampa, Florida, United States
13 Karmanos Cancer Institute and Wayne State University, Detroit, Michigan, United States
14 Karmanos Cancer Institute and Wayne State University, Detroit, Michigan, United States
15 Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah, United States
16 Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah, United States
17 University of Washington, Seattle, Washington, United States
18 University of Washington, Seattle, Washington, United States
19 University of Washington, Seattle, Washington, United States
20 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
21 University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
22 Tampa General Cancer Institute, Tampa, Florida, United States
23 Winship Cancer Institute of Emory University,, Emory, Georgia, United States
24 H. Lee Moffitt Cancer and Research Institute, Tampa, Florida, United States
25 Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Jacksonville, Florida, United States
26 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
27 Winship Cancer Institute of Emory University,, Emory, Georgia, United States
28 H. Lee Moffitt Cancer and Research Institute, Tampa, Florida, United States

Introduction: We have previously reported a 19.7-month median overall survival (mOS) in patients (pts) with CML-BP with a 5-year OS rate of 38%. A recent analysis from the ELN Blast Phase Registry developed a prognostic risk score for pts with CML-BP using six independent prognostic factors including blast percentage, platelets, age, immunophenotype of blasts, de novo blast phase vs blast phase progressed from prior chronic phase and presence of extramedullary disease (EMD). Herein, we sought to validate this prognostic model using the Cure CML Consortium blast phase dataset.

 

Methods: This multi-institution retrospective study included all pts diagnosed with CML-BP based on modified MD Anderson Criteria (≥30% blasts in the blood or bone marrow or EMD) from 2010 to 2025. Overall survival (OS) was calculated from time of diagnosis to death from any cause. Survival probabilities were computed using Kaplan–Meier method and compared with log-rank test. The prognostic score was derived using the following equation: 0.061 × (Blasts [%] / 10) – 0.082 × Platelets [per 100 × 109/L] + 0.034 × Age² / 100 – 0.405 [if de novo BP] – 0.865 [if lymphoid immunophenotype] + 0.541 [if extramedullary disease (EMD)] as per Lauseker et al. using the ELN Blast Phase Registry.

 

Results: Of the 284 pts with CML-BP, 98 (34.5%) were female and 186 (65.5%) were male. Median age at diagnosis of CML-BP was 50 (range 16-86) years. Seventy-nine pts (27.9%) were diagnosed with de novo BP, and 205 (72.1%) pts progressed from prior chronic or accelerated phase CML. EMD was present in 77 (27.1%) pts. Blasts were of myeloid phenotype in 180 (63.4%) and lymphoid in 104 (36.6%) pts. The bcr-abl transcript was p210 in 228 (80.3%), p190 in 8 (2.8%) and p230 in 2 (0.7%) pts.

The prognostic risk score was not able to be defined in 48 (16.9%) pts due to missing variables. Of the other 236 pts, 22 (7.7%) were categorized as having low risk, 137 (48.2%) as intermediate risk and 77 (27.1) pts as high-risk disease. OS differed significantly by risk group (p<0.0001). At a median follow-up of 47 months, patients in the high-risk group had the poorest outcomes, with a mOS of 10.3 months (95% CI, 6.44–14.00), compared with 25.9 months (95% CI, 18.10–65.61) in the intermediate-risk group, while the mOS was not reached in the low-risk group (p<0.0001). The 6-, 24-, and 60-month overall survival rates were 62%, 24%, and 14% for the high-risk group, 86%, 50%, and 39% for the intermediate-risk group, and 100%, 89%, and 83% for the low-risk group, respectively.

 

Conclusion: The Cure CML Consortium database successfully validated the ELN Blast Phase Registry prognostic risk score model by showing decrease OS for pts presenting with poor risk disease compared to those with intermediate or low risk presentations. This risk score does not include treatment related variables including TKI use, chemotherapy, and allogeneic stem cell transplant and it would be of interest to understand the impact of such treatments on outcomes in the risk groups. Despite these limitations, this prognostic risk score can be a useful tool while discussing prognosis with patients at initial diagnosis of BP disease.

Akriti G Jain, MD, FACP: Servier - Honoraria; Geron - Honoraria; PharmaEssentia - Honoraria; Takeda - Honoraria; Novartis - Honoraria; Servier - Research Funding; Novartis - Research Funding; PharmaEssentia - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); City Therapeutics - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)